Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?

Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be consider...

Full description

Bibliographic Details
Main Authors: Thomas Duflot, Ly Tu, Matthieu Leuillier, Hind Messaoudi, Déborah Groussard, Guillaume Feugray, Saïda Azhar, Raphaël Thuillet, Fabrice Bauer, Marc Humbert, Vincent Richard, Christophe Guignabert, Jérémy Bellien
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Metabolites
Subjects:
lysophospholipids
lysophosphatidic acids
cardiovascular diseases
HPLC-MS/MS
rodent models
pulmonary hypertension
Online Access:https://www.mdpi.com/2218-1989/11/11/784

Internet

https://www.mdpi.com/2218-1989/11/11/784

Similar Items